Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13904105 | 0.86 | CYP3A4 (0.34) | OGA | |
| SCHEMBL13903894 | 0.86 | CYP3A4 (0.34) | OGA | |
| SCHEMBL13904057 | 0.85 | APLNR (0.31) | — | |
| SCHEMBL13156629 | 0.79 | FFAR1 (0.34) | — | |
| SCHEMBL13156670 | 0.78 | RAB9A (0.32) | OGA | |
| SCHEMBL17082369 | 0.73 | APLNR (0.33) | — | |
| SCHEMBL12772099 | 0.73 | APLNR (0.32) | OGA | |
| SCHEMBL15385384 | 0.73 | — | — | |
| SCHEMBL15150406 | 0.73 | MEN1 (0.32) | OGA | |
| SCHEMBL15150405 | 0.72 | IDO1 (0.32) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082313-A1 | Multikinase Inhibitors for Use in the Treatment of Cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090048333-A1 | Zearalenone Macrolide Derivatives and Uses of the Same | EISAI CO., LTD. (JP) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082313-A1 | Multikinase Inhibitors for Use in the Treatment of Cancer | EGFR, ERBB3, FLT3 | OGA 3944/4885 |
| US-20090048333-A1 | Zearalenone Macrolide Derivatives and Uses of the Same | ZDHHC20, ZYX, SLC39A3 | OGA 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.